Merck KGaA Plays On Multiple Initiatives; Aims For 30% Growth In Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Contrary to what most global CEOs would say about challenges confronting the global pharmaceutical industry, Karl-Ludwig Kley, chairman of the $12.28 billion German chemicals and pharmaceuticals conglomerate Merck KGaA, says he doesn't believe the pharma business model is broken, despite dwindling R&D pipelines, increasing spend and diving sales as fewer blockbusters make it to market
You may also be interested in...
Merck KGaA Signs Cancer-MS Barter Deal With Japan's Ono
Why pay cash if you can barter asset rights instead? In a duo of agreements announced Oct. 4, Germany's Merck KGaA licensed worldwide rights ex-Japan, Korea and Taiwan to Ono Pharmaceutical Co. Ltd.'s Phase II MS candidate, ONO-4641, while granting Ono Japanese rights to its own Phase III cancer immunotherapy Stimuvax
Merck Serono Opens Bioanalysis Center In Beijing To Support Clinical Trials In Asia; Plans To Double Staff
SHANGHAI - Merck KGaA's biopharmaceutical arm Merck Serono SA opened Aug. 31 a new R&D laboratory in Beijing to establish bioanalysis capability that will support clinical trials in Asia. The site is on Chinese contract research organization Pharmaron's new campus in the Beijing Economic and Technological Development Area
Struggling Merck Serono Pins Hopes On New Management, Organization
One-time charges hit second quarter results; new management brought in to improve margins and productivity.